Tsuyoshi Minematsu

1.1k total citations
25 papers, 933 citations indexed

About

Tsuyoshi Minematsu is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Tsuyoshi Minematsu has authored 25 papers receiving a total of 933 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Oncology and 6 papers in Pharmacology. Recurrent topics in Tsuyoshi Minematsu's work include Drug Transport and Resistance Mechanisms (10 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Cell death mechanisms and regulation (5 papers). Tsuyoshi Minematsu is often cited by papers focused on Drug Transport and Resistance Mechanisms (10 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Cell death mechanisms and regulation (5 papers). Tsuyoshi Minematsu collaborates with scholars based in Japan, United States and United Kingdom. Tsuyoshi Minematsu's co-authors include Kathleen M. Giacomini, Takahito Nakahara, Masahiro Takeuchi, Isao Kinoyama, Masao Sasamata, Kentaro Yamanaka, Aya Kita, Kenna Shirasuna, Masafumi Kudoh and Takashi Usui and has published in prestigious journals such as Cancer Research, Life Sciences and Journal of Pharmaceutical Sciences.

In The Last Decade

Tsuyoshi Minematsu

24 papers receiving 917 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tsuyoshi Minematsu Japan	13	522	428	114	80	72	25	933
Gustav Lehne Norway	19	326 0.6×	427 1.0×	117 1.0×	56 0.7×	118 1.6×	46	950
Dietmar Schwab Switzerland	14	415 0.8×	305 0.7×	79 0.7×	50 0.6×	41 0.6×	26	1.1k
Anne-Charlotte Dubbelman Netherlands	17	386 0.7×	428 1.0×	45 0.4×	37 0.5×	109 1.5×	42	942
Diane D. Wang United States	14	191 0.4×	372 0.9×	90 0.8×	126 1.6×	154 2.1×	29	825
Narazah Mohd Yusoff Malaysia	17	448 0.9×	244 0.6×	137 1.2×	55 0.7×	139 1.9×	79	1.0k
Lee K. Tay United States	15	252 0.5×	548 1.3×	104 0.9×	111 1.4×	62 0.9×	33	1.1k
Satyakam Singh United States	20	571 1.1×	718 1.7×	129 1.1×	43 0.5×	95 1.3×	27	1.2k
Mian Gao United States	17	391 0.7×	612 1.4×	231 2.0×	81 1.0×	44 0.6×	28	1.0k
Hiromitsu Yokota Japan	20	579 1.1×	114 0.3×	47 0.4×	114 1.4×	63 0.9×	60	1.1k

Countries citing papers authored by Tsuyoshi Minematsu

Since Specialization

Citations

This map shows the geographic impact of Tsuyoshi Minematsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsuyoshi Minematsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsuyoshi Minematsu more than expected).

Fields of papers citing papers by Tsuyoshi Minematsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsuyoshi Minematsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsuyoshi Minematsu. The network helps show where Tsuyoshi Minematsu may publish in the future.

Co-authorship network of co-authors of Tsuyoshi Minematsu

This figure shows the co-authorship network connecting the top 25 collaborators of Tsuyoshi Minematsu. A scholar is included among the top collaborators of Tsuyoshi Minematsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsuyoshi Minematsu. Tsuyoshi Minematsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Poondru, Srinivasu, Peter L. Bonate, Rachel H. Rose, et al.. (2023). Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. Journal of Pharmacokinetics and Pharmacodynamics. 50(5). 365–376. 12 indexed citations

Nakamura, Koji, Yuichi Hanada, Satoshi Kubo, et al.. (2022). Preclinical Characterization of ASP2713, a Novel Igβ and FcγRIIB Cross-Linking Antibody, for Prediction of Human Pharmacokinetics and Clinically Effective Dose. Journal of Pharmaceutical Sciences. 111(9). 2630–2638.

Minematsu, Tsuyoshi, et al.. (2019). Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. Biopharmaceutics & Drug Disposition. 40(5-6). 176–187. 6 indexed citations

Minematsu, Tsuyoshi & Kathleen M. Giacomini. (2011). Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins. Molecular Cancer Therapeutics. 10(3). 531–539. 155 indexed citations

Minematsu, Tsuyoshi, et al.. (2011). Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein. Drug Metabolism and Disposition. 39(12). 2314–2320. 42 indexed citations

Kita, Aya, Takahito Nakahara, Masahiro Takeuchi, et al.. (2010). Survivin supressant: a promising target for cancer therapy and pharmacological profiles of YM155. Folia Pharmacologica Japonica. 136(4). 198–203. 6 indexed citations

Minematsu, Tsuyoshi, et al.. (2009). Characterization of Human Organic Cation Transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-Mediated Transport of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small Molecule Survivin Suppressant. Drug Metabolism and Disposition. 38(1). 1–4. 53 indexed citations

Minematsu, Tsuyoshi, et al.. (2009). Involvement of Human Organic Cation Transporter 1 in the Hepatic Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d ]imidazolium Bromide (YM155 Monobromide), a Novel, Small Molecule Survivin Suppressant. Drug Metabolism and Disposition. 37(9). 1856–1863. 15 indexed citations

Minematsu, Tsuyoshi, Jennifer Lee, Jiuhong Zha, et al.. (2009). Time-Dependent Inhibitory Effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-Dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.04.9]octacos-18-ene-2,3,10,16-tetrone (FK1706), a Novel Nonimmunosuppressive Immunophilin Ligand, on CYP3A4/5 Activity in Humans in Vivo and in Vitro. Drug Metabolism and Disposition. 38(2). 249–259. 7 indexed citations

10.

Minematsu, Tsuyoshi, T Hashimoto, Takashi Usui, & Hidetaka Kamimura. (2008). Characterization of renal tubular apical efflux of zonampanel, anα-amino-3-hydroxy-5- methylisoxazole-4-propionate receptor antagonist, in humans. Xenobiotica. 38(9). 1191–1202. 3 indexed citations

11.

Minematsu, Tsuyoshi, Kenji Sugimoto, Nobuaki Shirai, et al.. (2008). Carrier-Mediated Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d ]imidazolium Bromide (YM155 Monobromide), a Novel Small-Molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma Cells. Drug Metabolism and Disposition. 37(3). 619–628. 27 indexed citations

12.

Minematsu, Tsuyoshi, et al.. (2008). Role of Organic Anion Transporters in the Pharmacokinetics of Zonampanel, an α-Amino-3-hydroxy-5-methylisoxazole-4-propionate Receptor Antagonist, in Rats. Drug Metabolism and Disposition. 36(8). 1496–1504. 14 indexed citations

13.

Minematsu, Tsuyoshi, et al.. (2008). Liquid chromatography–electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small‐molecule survivin suppressant, in dog plasma. Biomedical Chromatography. 22(7). 763–769. 8 indexed citations

14.

Minematsu, Tsuyoshi, et al.. (2005). Identification of metabolites of [¹⁴C]zonampanel, an α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers. Xenobiotica. 35(4). 359–371. 4 indexed citations

15.

Minematsu, Tsuyoshi, Erika Sugiyama, Makiko Kusama, et al.. (2004). Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. Transplantation Proceedings. 36(5). 1506–1511. 31 indexed citations

16.

Hashimoto, Tadashi, Shinichi Narikawa, Xiu-Lin Huang, et al.. (2004). CHARACTERIZATION OF THE RENAL TUBULAR TRANSPORT OF ZONAMPANEL, A NOVEL α-AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID RECEPTOR ANTAGONIST, BY HUMAN ORGANIC ANION TRANSPORTERS. Drug Metabolism and Disposition. 32(10). 1096–1102. 17 indexed citations

17.

Minematsu, Tsuyoshi, Tadashi Hashimoto, Ken‐ichi Suzumura, et al.. (2004). Application of LC-NMR for Characterization of Rat Urinary Metabolites of Zonampanel Monohydrate (YM872). Chemical and Pharmaceutical Bulletin. 52(11). 1322–1325. 8 indexed citations

18.

Minematsu, Tsuyoshi, Hisakazu Ohtani, Yasuhiko Yamada, et al.. (2001). Quantitative Relationship Between Myocardial Concentration of Tacrolimus and QT Prolongation in Guinea Pigs: Pharmacokinetic/Pharmacodynamic Model Incorporating a Site of Adverse Effect. Journal of Pharmacokinetics and Pharmacodynamics. 28(6). 533–554. 47 indexed citations

19.

Minematsu, Tsuyoshi, Hisakazu Ohtani, Hitoshi Sato, & Tatsuji Iga. (1999). Sustained QT prolongation induced by tacrolimus in guinea pigs. Life Sciences. 65(14). PL197–PL202. 21 indexed citations

20.

Minematsu, Tsuyoshi, Hisakazu Ohtani, Hitoshi Sato, & Tatsuji Iga. (1999). Pharmacokinetic/Pharmacodynamic Analysis of Tacrolimus-Induced QT Prolongation in Guinea Pigs.. Biological and Pharmaceutical Bulletin. 22(12). 1341–1346. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact